New member: Welcome in our cluster to Yumab

Home  >>  News  >>  New member: Welcome in our cluster to Yumab

New member: Welcome in our cluster to Yumab

On March 13, 2019, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to Yumab

We are happy to welcome in our cluster Yumab:

 

Yumab

YUMAB develops fully human antibodies from target to lead for clients and partners worldwide.

Its proprietary antibody platform covers all technologies from antibody discovery – using one of the world’s largest, natural human antibody library collection (>10e11) or customized, patient-derived or immune libraries – to antibody engineering and lead optimization.

YUMAB antibodies contain natural, close to germ-line sequences promising low immunogenicity and toxicity. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability, early in the development process and provide high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels. Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats such as full-length IgG, Fab, scFv, bispecifics, CARs, fusion proteins and ADCs.

We are looking forward to see your active participation in the network!

You can find here more information abut Yumab.

Related Post

Comments are closed.